- Home
- URGN vs AMBC Comparison
URGN vs AMBC Comparison
Compare URGN & AMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- AMBC
- Stock Information
- Founded
- URGN 2004
- AMBC 1971
- Country
- URGN United States
- AMBC United States
- Employees
- URGN N/A
- AMBC N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- AMBC Property-Casualty Insurers
- Sector
- URGN Health Care
- AMBC Finance
- Exchange
- URGN Nasdaq
- AMBC Nasdaq
- Market Cap
- URGN 465.9M
- AMBC 388.0M
- IPO Year
- URGN 2017
- AMBC 1991
- Fundamental
- Price
- URGN $11.06
- AMBC $8.75
- Analyst Decision
- URGN Strong Buy
- AMBC Strong Buy
- Analyst Count
- URGN 6
- AMBC 2
- Target Price
- URGN $40.75
- AMBC $17.00
- AVG Volume (30 Days)
- URGN 418.3K
- AMBC 1.7M
- Earning Date
- URGN 03-10-2025
- AMBC 05-05-2025
- Dividend Yield
- URGN N/A
- AMBC N/A
- EPS Growth
- URGN N/A
- AMBC N/A
- EPS
- URGN N/A
- AMBC N/A
- Revenue
- URGN $90,398,000.00
- AMBC $240,754,000.00
- Revenue This Year
- URGN $43.60
- AMBC N/A
- Revenue Next Year
- URGN $103.77
- AMBC N/A
- P/E Ratio
- URGN N/A
- AMBC N/A
- Revenue Growth
- URGN 9.29
- AMBC 90.76
- 52 Week Low
- URGN $9.03
- AMBC $7.92
- 52 Week High
- URGN $20.70
- AMBC $18.45
- Technical
- Relative Strength Index (RSI)
- URGN 50.86
- AMBC 36.39
- Support Level
- URGN $11.12
- AMBC $8.52
- Resistance Level
- URGN $11.91
- AMBC $8.98
- Average True Range (ATR)
- URGN 0.57
- AMBC 0.32
- MACD
- URGN -0.02
- AMBC 0.12
- Stochastic Oscillator
- URGN 26.40
- AMBC 66.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.